Chesapeake Wealth Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Chesapeake Wealth Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,386	Closed	-$781K	–	165
2022 Q1	$781K	Buy	1,386 +5	+0.4%	+$3.01K	0.28%	88
2021 Q4	$1.04M	Buy	1,381 +75	+6%	+$56.1K	0.35%	73
2021 Q3	$974K	Sell	1,306 -104	-7%	-$77.9K	0.35%	70
2021 Q2	$909K	Sell	1,410 -53	-4%	-$32.3K	0.29%	85
2021 Q1	$836K	Buy	1,463 +297	+25%	+$176K	0.28%	91
2020 Q4	$680K	Buy	1,166 +52	+5%	+$29.6K	0.23%	101
2020 Q3	$574K	Buy	1,114 +236	+27%	+$120K	0.21%	109
2020 Q2	$396K	Buy	+878	New	+$387K	0.16%	136

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Chesapeake Wealth Management's BIO Position: Q2 2022 in Review

Chesapeake Wealth Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 1,386 shares — an estimated $781K sold.

Chesapeake Wealth Management first reported a position in BIO in Q2 2020 and held it in 8 quarters. The position peaked at $1.04M in Q4 2021. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

Chesapeake Wealth Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
Chesapeake Wealth Management sold 1,386 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $781K.
Chesapeake Wealth Management first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 8 quarters.
Chesapeake Wealth Management's Bio-Rad Laboratories Class A position peaked at $1.04M in Q4 2021.
500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on Chesapeake Wealth Management's 13F filing for Q2 2022, filed 21 Jul 2022.